Reliance of Indian pharma industry on Chinese APIs a 'huge strategic concern' with few short-term solutions, they say; meanwhile, CSIR says Covid offers a good opportunity to check brain drain
The solution uses advanced analytics to manage individual patient treatment lifecycle from enrolment and scheduling to post medical treatments and can notably reduce patient treatment lifecycle
Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late
The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug
On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.
For manufactured products, the stated policy since the 1950s was to allow imports of only the goods that were not being made in India in sufficient quantities